Answers are grounded in this paper and cite their sources.
Malignant cerebral glioma Modern radiotherapy can give good quality survival for six monthsEditor-We wish to correct misinformation reported by Elizabeth Davies and colleagues in their study of survival after radiotherapy for malignant cerebral glioma. 1 Contrary to their suggestion in the acknowledgements, the study had not been supported by the Medical Research Council Brain Tumour Working Party.As the poor study design indicates, the study had never been officially submitted to the Medical Research Council and had therefore not been subjected to its rigorous protocol review process.For example, Davies and colleagues report that their criteria for assessment of treatment toxicity were derived in a "pragmatic fashion after discussion" by a "process of elimination," without evidence from imaging to exclude tumour progression.This would be totally unacceptable, let alone publishable.The impression that the 105 patients represent an unselected consecutive series is difficult to believe as the seven centres should, over two years, have seen 400-800 eligible patients. 2 The reported adverse prognostic factors in patients with high grade glioma have been known for over 18 years. 3Although the authors appropriately conclude that severely disabled patients have a poor prognosis and may not be suitable for active treatment, the fact that they were considered for intensive treatment at all is surprising.Centres specialised in the treatment of patients with brain tumours would not have accepted patients with such a poor prognosis for high dose radiotherapy.Most of the patients also seemed to receive initial whole brain radiotherapy followed by a radiation boost to the tumour.Whole brain radiotherapy is nothing but toxic and has not been practised in specialist centres for many years.Given the use of outdated and often inappropriate high dose, wide field radiotherapy and the flawed assessment of morbidity from treatment, the conclusion that radiation is of little value and simply results in adverse effects seems ill advised.High grade gliomas are among the most devastating of malignancies, with few useful treatment options.Modern radiotherapy, although not curative, offers a survival benefit of about six months, 3 and for most patients without functional impairment the quality of survival is good.Without com-parative data on the quality of life, how can we decide whether prolongation of survival by six months with clinical deterioration in a small proportion of patients is worse than the alternative of progressive functional decline, which happens in all patients without treatment?Yes, we do need more effective treatments without morbidity, but to throw out a proved treatment on the basis of misinformation is a travesty to evidence based medicine, to which the BMJ claims allegiance.
No takes yet. Share an insight, caveat, or question.
Kennedy et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: